[Iopromide 370 in coronaroventriculography, versus ioxaglate 320 mg/ml].
Twenty-four patients with angina were included in a prospective randomized trial, comparing a new non-ionic contrast medium--iopromide 370 mgI/ml--versus the ionic low osmolar contrast medium, ioxaglate 320 mgI/ml. Twelve received iopromide 370 and twelve ioxaglate 320 mgI/ml. The main topic of this study was general and cardiac safety. Cardiac safety was monitored by EKG and diastolic and systolic blood pressures. In spite of a bias--5 patients with iopromide 370 had myocardial infarction, versus one with ioxaglate 320--there were fewer adverse effects with iopromide 370. The population of only 24 failed to reveal a statistically significant difference, but the tendency was confirmed by the meta-analysis of this multicentric study.